SSanifit
Acquired by Vifor Pharma, 2022.
Sanifit no longer appears in the directory or on the maps; no funding rounds are on record.
Source ↗
Sanifit (Laboratoris Sanifit S.L.) was a clinical-stage biopharmaceutical company founded in Palma de Mallorca as a spin-off of the University of the Balearic Islands, developing SNF472 (hexasodium fytate), a calcification inhibitor for calciphylaxis and peripheral artery disease in end-stage kidney disease patients. It reached Series D, raising roughly €130M+ total, including a €72.2M round in 2019 that was then Spain's largest private biotech fundraise. Sanifit no longer exists as an independent company: it was acquired by Vifor Pharma in 2021 for €205M upfront (up to €375M plus milestones), and Vifor was subsequently absorbed into CSL.
SectorsBiotech, Pharmaceuticals, Healthtech & Bio, Nephrology, Rare Diseases
Founders
B
Bernat Isern
Co-founder
Global models
No comparables on record yet.
In the same niche 68 others
See all in the Start-ups Map →
Notes: Most funded first
Investors 9
Open as list →
AAlta Life Sciences
www.altals.com
CColumbus Venture Partners
columbusvp.com
CCriteria Capital Risc
www.criteriaventures.com
YYsios Capital
ysioscapital.com
AAndera Partners
FForbion
GGilde Healthcare
HHealthEquity (HealthEquity Ventures)
LLundbeckfonden Ventures
Funding rounds
No announced rounds on record.
News 2
Open as list →| Published | Article |
|---|---|
| 2026-03-27 |
Ysios Capital launches €100M fund to build biotech companies from Spanish science ↗
TNW (The Next Web)
2026-03-27 |
| 2024-12-06 |
Calciphylaxis: Hexasodium Fytate as a Potential Treatment for a Devastating Disease ↗
ASN Kidney News
2024-12-06 |